SCHEMBL1458413

SCHEMBL1458413

COC(=O)c1cc(Cl)c(OCc2ccccc2)c(Cl)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.74
HPGD P15428 2/20 0.74
KDM4E B2RXH2 2/20 0.57
ALDH1A1 P00352 4/20 0.50
TSHR P16473 2/20 0.50
GLRA1 P23415 1/20 0.50
USP2 O75604 1/20 0.50
HSD17B10 Q99714 1/20 0.50
PPARG P37231 1/20 0.49
PPARA Q07869 1/20 0.49
MRGPRX4 Q96LA9 3/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
ABL1 P00519 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
RAB9A P51151 1/20 0.48
RIN1 Q13671 1/20 0.48
ADCYAP1R1 P41586 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458077 0.93 LMNA (0.82) LMNAHPGDKDM4EALDH1A1TSHR
SCHEMBL28857697 0.87 KMT2A (0.60) LMNAHPGDKDM4EALDH1A1GLRA1
SCHEMBL1458102 0.86 PLAU (0.57) LMNAHPGDKDM4EALDH1A1MEN1
SCHEMBL1458188 0.86 LMNA (0.60) LMNAHPGDKDM4EALDH1A1GLRA1
SCHEMBL4241842 0.86 KDM4E (0.62) LMNAHPGDKDM4EALDH1A1GLRA1
SCHEMBL21408252 0.85 LMNA (0.74) LMNAHPGDKDM4EALDH1A1TSHR
SCHEMBL16250484 0.85 LMNA (1.00) LMNAHPGDKDM4EALDH1A1TSHR
SCHEMBL5918942 0.85 KDM4E (0.60) LMNAHPGDKDM4EALDH1A1GLRA1
SCHEMBL1457712 0.84 MEN1 (0.63) LMNAHPGDKDM4EGLRA1MRGPRX4
SCHEMBL10397791 0.84 HPGD (0.58) LMNAHPGDKDM4EALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 US disclosed
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 US disclosed
EP-4214189-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL Business Ltd (GB) 2023-07-26 EP disclosed
WO-2022058733-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS PLC (GB) 2022-03-24 WO disclosed
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20090111862-A1 Compound RICHTER GEDEON NYRT. (HU) 2009-04-30 US disclosed
US-7361677-B2 Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase STERIX, LTD. (GB) 2008-04-22 US disclosed
US-7361677-B2 Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase STERIX, LTD. (GB) 2008-04-22 US disclosed
US-7361677-B2 Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase STERIX, LTD. (GB) 2008-04-22 US disclosed
US-20060241173-A1 A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers STERIX LTD. 2006-10-26 US disclosed
US-7098343-B2 Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor STERIX, LIMITED (GB) 2006-08-29 US disclosed
US-20060142360-A1 Compound RICHTER GEDEON NYRT. (HU) 2006-06-29 US disclosed
EP-1446388-A1 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS Sterix Limited (GB) 2004-08-18 EP disclosed
US-20040019016-A1 Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor RICHTER GEDEON NYRT. (HU) 2004-01-29 US disclosed
WO-2003045925-A1 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS STERIX LIMITED (GB) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111862-A1 Compound QPCT, SQOR, SDHA LMNA 3101/4885HPGD 488/4885KDM4E 257/4885
US-20060241173-A1 A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers STS, SULT1E1, CYP19A1 LMNA 4555/4885HPGD 720/4885KDM4E 1320/4885
US-20060142360-A1 Compound QPCT, SQOR, SDHA LMNA 3101/4885HPGD 488/4885KDM4E 257/4885
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS TTR, C1R, APOB LMNA 63/4885HPGD 3194/4885KDM4E 4178/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG LMNA 1825/4885HPGD 1259/4885KDM4E 2548/4885
US-20040019016-A1 Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor STS, CYP21A2, SULT1E1 LMNA 4378/4885HPGD 484/4885KDM4E 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.